Kaken Pharmaceutical Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, Kaken Pharmaceutical stock has a consensus rating of "Hold" and an average price target of ¥4,350. The average 1-year stock price forecast is 13.73% higher than the current stock price, while the lowest is ¥3,600 (-5.88%) and the highest is ¥5,300 (+38.56%).

Price Target: ¥4,350 (+13.73%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	¥3,600	¥4,350	¥4,250	¥5,300
Change	-5.88%	+13.73%	+11.11%	+38.56%

Analyst Ratings

The average analyst rating for Kaken Pharmaceutical stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	0	0	0	0	0	0
Buy	1	1	1	1	1	1
Hold	2	2	2	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	4	4	4

Financial Forecast

Revenue This Year

79.65B

from 76.87B

3.61%

from 76.87B

Revenue Next Year

81.42B

from 79.65B

2.22%

from 79.65B

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	76.03B	72.98B	72.04B	94.04B	76.87B	79.65B
Revenue Growth	1.41%	-4.01%	-1.29%	30.52%	-18.25%	3.61%
Gross Profit	41.58B	39.56B	38.54B	58.53B	39.99B	42.82B
Gross Margin	54.68%	54.20%	53.49%	62.25%	52.02%	53.76%
Operating Income	17.07B	8.00B	9.51B	21.04B	-899.00M	4.40B
Net Income	9.55B	5.44B	8.03B	13.95B	2.14B	3.23B
Dividend / Share	150.00	150.00	150.00	150.00	-	190.00
Free Cash Flow	8.03B	7.49B	-1.30B	22.98B	-14.29B	8.54B
No. Analysts	-	-	-	-	-	4

Financial currency is JPY.

Revenue Forecast

Revenue	2027	2028	2029
High	89.0B
Avg	79.6B
Low	73.3B

Revenue Growth

Revenue Growth	2027	2028	2029
High	15.8%
Avg	3.6%
Low	-4.6%

EPS Forecast

EPS	2027	2028	2029
High	-
Avg	-
Low	-

EPS Growth

EPS Growth	2028	2029
High	-
Avg	-
Low	-